| Quantity | 1 mg, 5 mg, 10 mg, 25 mg | 1 mg, 5 mg, 10 mg, 25 mg | 10 mM * 1 mL, 5 mg, 10 mg, 25 mg | 10 KU | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | PADRE peptide is a universal peptidic epitope. PADRE peptide binds to pan HLA-DR receptors, present on specific T cells. PADRE peptide can be inserted into trichodysplasia spinulosa-associated polyomavirus (TSPyV) viral protein 1 (VP1) or hamster polyomavirus (HaPyV)-derived VP1 for construction of PADRE peptide is a universal peptidic epitope. PADRE peptide binds to pan HLA-DR receptors, present on specific T cells. PADRE peptide can be inserted into trichodysplasia spinulosa-associated polyomavirus (TSPyV) viral protein 1 (VP1) or hamster polyomavirus (HaPyV)-derived VP1 for construction of chimeric virus-like particles (VLPs), therefore activating dendritic cells and T cells and inducing strong immune responses and. PADRE peptide can be used for the development of vaccines[1]... Read More | Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosisBulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2]... Read More | DAMGO TFA is a µ-opioid receptor (µ-OPR ) selective agonist with a Kd of 3.46 nM for native µ-OPR[1] | PNGase F, a glycosidase, catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. PNGase F removes nearly all N-linked oligosaccharides from glycoproteins. PNGase F can release N-glycans from glycoproteins in glycoanalytical workflows[1][2] | RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities[1][2]... Read More |